Literature DB >> 17505825

Combination of doxorubicin and low-intensity ultrasound causes a synergistic enhancement in cell killing and an additive enhancement in apoptosis induction in human lymphoma U937 cells.

Toru Yoshida1, Takashi Kondo, Ryohei Ogawa, Loreto B Feril, Qing-Li Zhao, Akihiko Watanabe, Kazuhiro Tsukada.   

Abstract

PURPOSE: Potential clinical use of ultrasound (US) in enhancing the effects of anticancer drugs in the treatment of cancers has been highlighted in previous reports. Increased uptake of drugs by the cancer cells due to US has been suggested as a mechanism. However, the precise mechanism of the enhancement has not yet been elucidated. Here, the combined effects of low-intensity pulsed US and doxorubicin (DOX) on cell killing and apoptosis induction of U937 cells, and mechanisms involved were investigated.
METHODS: Human myelomonocytic lymphoma U937 cells were used for the experiments. Experiments were conducted in 4 groups: (1) non-treated, (2) DOX treated (DOX), (3) US treated (US), and (4) combined (DOX + US). In DOX +US, cells were exposed to 5 microM DOX for 30 min and sonicated by 1 MHz pulsed US (PRF 100 Hz, DF 10%) at intensities of 0.2-0.5 W/cm(2) for 60 s. The cells were washed and incubated for 6 h. The viability was evaluated by Trypan blue dye exclusion test and apoptosis and incorporation of DOX was assessed by flow cytometry. Involvement of sonoporation in molecular incorporation was evaluated using FITC-dextran, hydroxyl radical formation was measured by electron paramagnetic resonance-spin trapping, membrane alteration including lipid peroxidation and membrane fluidity by DOX was evaluated using cis-parinaric acid and perylene fluorescence polarization method, respectively.
RESULTS: Synergistic enhancement in cell killing and additive enhancement in induction of apoptosis were observed at and above 0.3 W/cm(2). No enhancement was observed at 0.2 W/cm(2) in cell killing and induction of apoptosis. Hydroxyl radicals formation was detected at and above 0.3 W/cm(2). The radicals were produced more in the DOX + US than US alone. Incorporation of DOX was increased 13% in DOX + US (vs. DOX) at 0.5 W/cm(2). Involvement of sonoporation for increase of drug uptake was suggested by experiment using FITC-labeled dextran. We made the hypothesis that DOX treatment made the cells weaken against the mechanical effect of the US. Although treatment of DOX at 5 microM for 30 min did not affect lipid peroxidation and fluidity of cell membrane significantly, higher concentration and longer treatment of DOX induced the significant alteration of cell membrane.
CONCLUSION: Mechanisms of enhancements could be (1) increase in incorporation of the DOX by US involved with sonoporation, (2) enhancement of the cavitation by DOX. Cavitation is required for the enhancement of the effect of DOX. Although the precise involvement of the membrane modifications by DOX in the enhancement remains to be elucidated, they could be involved in the latent effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505825     DOI: 10.1007/s00280-007-0503-y

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

Review 1.  A review of low-intensity ultrasound for cancer therapy.

Authors:  Andrew K W Wood; Chandra M Sehgal
Journal:  Ultrasound Med Biol       Date:  2015-04       Impact factor: 2.998

2.  Low-intensity ultrasound adjuvant therapy: enhancement of doxorubicin-induced cytotoxicity and the acoustic mechanisms involved.

Authors:  Takashi Kondo; Toru Yoshida; Ryohei Ogawa; Mariame A Hassan; Yukihiro Furusawa; Qing-Li Zhao; Akihiko Watanabe; Akihiro Morii; Loreto B Feril; Katsuro Tachibana; Hiroshi Kitagawa; Yoshiaki Tabuchi; Ichiro Takasaki; Mohammad H Shehata; Nobuki Kudo; Kazuhiro Tsukada
Journal:  J Med Ultrason (2001)       Date:  2009-06-17       Impact factor: 1.314

3.  Differential cytotoxicity and sonosensitization by sanazole: effect of cell type and acoustic parameters.

Authors:  Mariame A Hassan; Yukihiro Furusawa; Qing-Li Zhao; Ichiro Takasaki; Loreto B Feril; Katsuro Tachibana; Nobuki Kudo; Masami Minemura; Toshiro Sugiyama; Takashi Kondo
Journal:  J Med Ultrason (2001)       Date:  2011-01-05       Impact factor: 1.314

4.  Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitro.

Authors:  Nahyoung G Lee; Jesse L Berry; Tom C Lee; Annie T Wang; Scott Honowitz; A Linn Murphree; Neeta Varshney; David R Hinton; Amani A Fawzi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

5.  Construction of artificial promoters sensitively responsive to sonication in vitro.

Authors:  Akihiko Watanabe; Satoshi Kakutani; Ryohei Ogawa; Sung-Il Lee; Toru Yoshida; Akihiro Morii; Go Kagiya; Loreto B Feril; Hideki Fuse; Takashi Kondo
Journal:  J Med Ultrason (2001)       Date:  2009-03-14       Impact factor: 1.314

Review 6.  Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles.

Authors:  Chiranjeevi Peetla; Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2013-09-19       Impact factor: 15.470

Review 7.  Current status and future perspective of sonodynamic therapy for cancer.

Authors:  Atsushi Sofuni; Takao Itoi
Journal:  J Med Ultrason (2001)       Date:  2022-10-12       Impact factor: 1.878

8.  Ultrasound-induced new cellular mechanism involved in drug resistance.

Authors:  Mariame A Hassan; Yukihiro Furusawa; Masami Minemura; Natalya Rapoport; Toshiro Sugiyama; Takashi Kondo
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

9.  Low-intensity ultrasound enhances the anticancer activity of cetuximab in human head and neck cancer cells.

Authors:  Takashi Masui; Ichiro Ota; Masatoshi Kanno; Katsunari Yane; Hiroshi Hosoi
Journal:  Exp Ther Med       Date:  2012-10-10       Impact factor: 2.447

Review 10.  Using the Promise of Sonodynamic Therapy in the Clinical Setting against Disseminated Cancers.

Authors:  Matthew Trendowski
Journal:  Chemother Res Pract       Date:  2015-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.